LifeMD, Inc.

NASDAQ:LFMD

Medical - Pharmaceuticals

Healthcare
$1.70 -3.27%

-$0.16 today

Market cap
$82.17M
Beta
1.99
P/E (TTM)
-13.8
EPS (TTM)
-$0.34
52W Low $2.56High $15.84

Volume 0.80M

Average 1.04M

LFMD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

LifeMD, Inc.NASDAQ: LFMD

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $2.55M a year earlier. Trailing-twelve-month stock-based compensation was $7.95M. Over 3 fiscal years it compounded at -8.6% a year.

Context

  • Stock-based compensation amounted to 5.4% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.99M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$10.5M-14.2% YoY
LTMMar 2026
$7.95M-35.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-14.2%——
3-year CAGR-8.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.5M USD
Year-over-year change
-14.2%
4-year CAGR
-3.4%

Stock-Based Compensation vs competitors

How LFMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.1% is the 8th highest of 10, against a peer median of -10.6%.
  • Stock-based compensation amounts to 3.6% of revenue for LFMD, versus a peer median of 9.5%.
LFMD Competitors
Stock-Based Compensation for LFMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CERSCerus CorporationLTM Mar 2026$21.14M USD-10.6%-2.2%9.5%
TBRGTruBridge, Inc.LTM Mar 2026$17.06M USD+187.5%+18.7%4.9%
SGHTSight Sciences, Inc.LTM Mar 2026$11.67M USD-30.6%+0.2%14.7%
CVRXCVRx, Inc.LTM Mar 2026$11.51M USD+11.1%+41.7%19.5%
SENSSenseonics Holdings, Inc.LTM Mar 2026$10.59M USD+14.3%+5.6%26.0%
MASS908 Devices Inc.LTM Mar 2026$9.88M USD-14.0%+11.0%17.1%
LFMDLifeMD, Inc.LTM Mar 2026$7.95M USD-35.1%-8.6%3.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.42M USD+1.9%-2.6%5.8%
HITIHigh Tide Inc.LTM Apr 2026CA$1.86M CAD-54.1%-21.4%0.3%
SMTISanara MedTech Inc.LTM Mar 2026$442.14K USD-91.0%-35.7%0.4%
Peer median (excluding LFMD) —-10.6%+0.2%9.5%

Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(61.32M)(45.02M)(20.6M)(18.73M)15.62M
Depreciation & Amortization868.76K3.77M6.6M9.49M328.37K
Deferred Income Tax0354K000
Stock-Based Compensation12.07M13.73M12.49M12.23M10.5M
Change in Working Capital9.13M(1.55M)4.91M12.65M(7.85M)
Accounts Receivables17.7K(2.19M)(2.44M)(2.94M)1.15M
Inventory(409.82K)(2.18M)764.33K675.67K303.24K
Accounts Payables(893.96K)1.25M978.06K4.92M3.24M
Other Working Capital10.42M1.58M5.61M9.99M(12.55M)
Other Non-Cash Items6.17M5.78M5.42M1.87M(10.31M)
Operating Cash Flow(33.09M)(22.94M)8.82M17.51M8.28M
Capital Expenditures(3.4M)(12.89M)(8.73M)(11.54M)(9.52M)
Acquisitions (Net)0(1.01M)000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(3.15M)(12.53M)(8.53M)(10.05M)8.78M
Investing Cash Flow(3.4M)(13.91M)(8.73M)(11.54M)6.91M
Debt Repayment(530.82K)2.74M16.67M(327.6K)(18.72M)
Common Stock Issued13.99M016.2M09.19M
Common Stock Repurchased00000
Dividends Paid(871.48K)(3.11M)(3.11M)(3.11M)(3.11M)
Other Financing Activities707.36K(159.2K)(667.63K)(684.83K)(773.66K)
Financing Cash Flow68.64M(528.2K)29.1M(4.12M)(13.41M)
Effect of Forex Changes00000
Net Change in Cash32.15M(37.37M)29.19M1.86M1.78M
Free Cash Flow(36.49M)(35.83M)86.95K5.98M(1.24M)

LifeMD, Inc.

NASDAQ:LFMD

Intrinsic Alpha fair value

Locked

Current Price

$1.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.